Today: 22 May 2026
Browse Category

NASDAQ:CSGP 15 December 2025 - 17 May 2026

CoStar Set to Drop from Nasdaq-100 Monday: What’s Next for CSGP Holders

CoStar Set to Drop from Nasdaq-100 Monday: What’s Next for CSGP Holders

CoStar closed at $32.68 Friday, up 2.6%, with trading volume surging ahead of its removal from the Nasdaq-100. Nasdaq said Lumentum will replace CoStar in the index before Monday’s open. Index funds tracking the Nasdaq-100 may adjust holdings as a result. CoStar’s first-quarter revenue rose 23% to $897 million, but its residential segment posted a $29 million adjusted EBITDA loss.
17 May 2026
···
CoStar Group Stock (CSGP) Slumps as Google Tests Home Listings in Search: Latest News, Forecasts, and Outlook (Dec. 15, 2025)

CoStar Group Stock (CSGP) Slumps as Google Tests Home Listings in Search: Latest News, Forecasts, and Outlook (Dec. 15, 2025)

CoStar Group shares fell 7%–8% to around $63 on Monday after reports that Google is testing home-for-sale listings directly in search results. The move raised concerns about potential disruption to real estate portals’ lead generation models. The test, limited to certain users and markets, also pressured shares of Zillow and Rocket. Analysts cited limited immediate impact but noted risk if Google expands the feature.
15 December 2025
··

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
Go toTop